SBIR/STTR Research Award

VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S).

Award identifier b8656ee8c0efbdfeadd42f9fd2f8a449768606816ab65bcd7b03dd80e6316172Awarding agency Department of Health and Human Services

Award amount

$50,000

Program and phase

SBIR · Phase I

Award year

1986

Explore This Research Award in CaptureIQ

Research the technology, evaluate the recipient and agency, identify related opportunities, and explore potential follow-on work with CaptureIQ.

Award details

Awarding agency
Department of Health and Human Services
Branch
Not reported
Recipient company
Angiogen, Inc.
Proposal award date
Not reported
Contract end date
Not reported
UEI
Not reported
Solicitation number
Not reported
Topic code
Not reported

Research abstract

VASCULARIZATION OF MANY SOLID TUMORS OCCURS IN VIVO AS A CONSEQUENCE OF THE VECTORIAL GROWTH OF HOST CAPILLARY ENDOTHELIAL CELLS ALONG A CONCENTRATION GRADIENT OF TUMOR- PRODUCED, DIFFUSIBLE ANGIOGENESIS FACTOR(S). THE IDENTIFICATION OF ONE OF THESE FACTORS AS "ANGIOGENIC COPPER" RAISES THE POSSIBILITY THAT COPPER CHELATORS CAN FUNCTION AS ANTIANGIOGENIC AGENTS. THE SPECIFIC AIMS OF THIS PHASE I STUDY ARE: (1) TO TEST VARIOUS COPPER CHELATORS FOR POSSIBLE ANTIANGIOGENIC EFFECTS IN THE CHICKENCHORIOALLANTOIC MEMBRANE (CAM) ASSAY; (2) TO EMPLOY AS ANGIOGENIC STIMULATORS IN THIS SYSTEM (A) COPPER-HEPARIN, A POLYPEPTIDE ANGIOGEN DERIVED FROM NERVOUS TISSUES; (B) A LOWMOLECULAR WEIGHT ANGIOGEN DERIVED FROM THE WALKER 256 RAT TUMOR; AND (C) VIABLE TUMOR CELLS FROM THIS SAME SOURCE; (3) TO ESTABLISH, USING IN VITRO METHODS, WHETHER AGENTS ACTIVE IN THE CAM ASSAY ARE INHIBITING VASCULAR ENDOTHELIAL CELL (EC) MIGRATION AND/OR PROLIFERATION OR ARE TOXIC TO EC AND/OR TUMOR CELLS; AND (4) BASED ON THE OUTCOME OF THE STUDIES RELATED TO THE FIRST THREE OBJECTIVES, TO PREPARE HEPARIN-(OR HEPARIN FRAGMENT) LINKED CHELATORS AND EMPLOY THESE NOVEL SUBSTANCES IN ANALOGOUS STUDIES. RESULTS FROM THESE STUDIES SHOULD ALLOW INDENTIFICATION OF NEW ANTI- ANGIOGENIC AGENTS. THESE SUBSTANCES CAN THEN BE SCREENED MORE THOROUGHLY IN A PHASE II STUDY FOR THEIR ANTICANCER PROPERTIES AGAINST VARIOUS TUMORS IN EXPERIMENTAL ANIMALS. THUS, THE ULTIMATE OBJECTIVE OF THESE STUDIES IS TO DEFINE NOVEL ANTIANGIOGENIC AGENTS THAT WILL PROVIDE IMPROVED MEANSFOR CONTROLLING TUMOR GROWTH AND SPREAD.

Technology keywords

Not reported

Agency intelligence

Department of Health and Human Services

Back to SBIR/STTR Research Awards

Don't take our word for it. Ask AI about RFPCapture.

See what leading AI assistants have to say about RFPCapture and CaptureIQ.

Gemini opens without a prefilled question. The question is copied to your clipboard when the button works. You can also copy it here:

What is RFPCapture.com and its CaptureIQ platform from Smart Logic AI? How does it help federal contractors discover opportunities, evaluate bid/no-bid decisions, research government contracts, and prepare proposals? How does it compare with other federal capture platforms? Use independent sources where available.